Contrast-enhanced ultrasound techniques for guiding and assessing response to locoregional treatments for hepatocellular carcinoma

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 68-77

  Andreana, Lorenzo ^a,b   Kudo, Masatoshi ^b   Hatanaka, Kinuyo ^b   Chung, Hobyung ^b   Minami, Yasunori ^b   Maekawa, Kiyoshi ^b   Ruggiero, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Contrast enhanced ultrasound; Embolization; Hepatocellular carcinoma; Percutaneous ablation

Indexed keywords

PERFLEXANE; PERFLUBUTANE; PERFLUTREN; SHU 508; SONOVUE;

ARTIFICIAL EMBOLISM; CONTRAST ENHANCEMENT; ECHOGRAPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FERRIC COMPOUNDS; HUMANS; IRON; LIVER NEOPLASMS; OXIDES; TREATMENT OUTCOME;

EID: 77954511343     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315233     Document Type: Review

References (74)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Pleguezuelo M, Germani G, Marelli L, et al: Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008; 2: 761-784.
4. Bruix J, Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
5. Germani G, Pleguezuelo M, Gurusamy K, et al: Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; 52: 380-388.
6. Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
7. Lin DY, Lin SM, Liaw YF: Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12:S319-S328.
8. Solbiati L, Ierace T, Goldberg SN, et al: Percutaneous US-guided radiofrequency tissue ablation of liver metastases: treatment and follow-up in 16 patients. Radiology 1997; 202: 195-203.
9. Hashimoto M, Watanabe O, Hirano Y, et al: Use of carbon dioxide microbubble-enhanced sonographic angiography for transcatheter arterial chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 1997; 169: 1307-1310.
10. Bruix J, Sherman M, Llovet JM, et al: EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
11. Kudo M, Hatanaka K, Maekawa K: Defect reperfusion Imaging, a newly developed novel technology using Sonazoid in the treatment of hepatocellular carcinoma. J Med Ultrasound 2008; 16: 169-176.
12. Kudo M, Tomita S, Tochio H, et al: Small hepatocellular carcinoma: diagnosis with US angiography with intraarterial CO 2 microbubbles. Radiology 1992; 182: 155-160.
13. Miyamoto N, Hiramatsu K, Tsuchiya K, et al: Carbon dioxide microbubbles-enhanced sonographically guided radiofrequency ablation: treatment of patients with local progression of hepatocellular carcinoma. Radiat Med 2008; 26: 92-97.
14. Imari Y, Sakamoto S, Shiomichi S, et al: Hepatocellular carcinoma not detected with plain US: treatment with percutaneous ethanol injection under guidance with enhanced US. Radiology 1992; 185: 497-500.
15. Takeshima K, Kumada T, Kimura T, et al: The usefulness of percutaneous ethanol injection therapy under guidance with carbon dioxide contrast-enhanced ultrasound sonography. Nippon Rinsho 1998; 56: 1001-1006.
16. Numata K, Tanaka K, Kiba T, et al: Nonresectable hepatocellular carcinoma: improved percutaneous ethanol injection therapy guided by CO 2-enhanced sonography. AJR Am J Roentgenol 2001; 177: 789-798.
17. Miyajima Y, Sakaguchi S, Tohara K: Transcatheter arterial embolization of hepatocellular carcinoma using CO 2 US. Nippon Rinsho 1998; 56: 990-993.
18. Irie T, Yamada T, Ganaha F, et al: Usefulness of CO 2 US angiography in treating hepatocellular carcinoma. Nippon Igaku Hoshasen Gakkai Zasshi 1998; 58: 338-342.
19. Shirato K, Morimoto M, Tomita N, et al: Hepatocellular carcinoma: therapeutic experience with percutaneous ethanol injection under real-time contrast-enhanced color Doppler sonography with the contrast agent Levovist. J Ultrasound Med 2002; 21: 1015-1022.
20. Numata K, Isozaki T, Ozawa Y, et al: Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma. AJR Am J Roentgenol 2003; 180: 143-149.
21. Minami Y, Kudo M, Kawasaki T, et al: Percutaneous radiofrequency ablation guided by contrast-enhanced harmonic sonography with artificial pleural effusion for hepatocellular carcinoma in the hepatic dome. AJR Am J Roentgenol 2004; 182: 1224-1226.
22. Numata K, Morimoto M, Ogura T, et al: Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med 2008; 27: 395-406.
23. Maruyama H, Takahashi M, Ishibashi H, Okugawa H, Okabe S, Yoshikawa M, Yokosuka O: Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 2009; 29: 708-714.
24. Miyamoto N, Hiramatsu K, Tsuchiya K, et al: Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 2009; 27: 185-193.
25. Solbiati L, Ierace T, Tonolini M, et al: Guidance and control of percutaneous treatments with contrast-enhanced ultrasound. Eur Radiol 2003; 13(suppl 3):N87-N90.
26. Maruyama H, Kobayashi S, Yoshizumi H, et al: Application of percutaneous ultrasoundguided treatment for ultrasonically invisible hypervascular hepatocellular carcinoma using microbubble contrast agent. Clin Radiol 2007; 62: 668-675.
27. Minami Y, Kudo M, Chung H, et al: Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. AJR Am J Roentgenol 2007; 188: 489-494.
28. Tamai H, Oka M, Maeda H, et al: Contrast harmonic sonographically guided radiofrequency ablation for spontaneous ruptured hepatocellular carcinoma. J Ultrasound Med 2005; 24: 1021-1026.
29. Zhu LX, Wang GS, Fan ST: Spontaneous rupture of hepatocellular carcinoma. Br J Surg 1996; 83: 602-607.
30. Uchida K, Nakata S, Iwase H, et al: Imaging diagnosis of ruptured site in hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi 1989; 86: 1287-1291.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
32. Forner A, Ayuso C, Varela M, et al: Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-623.
33. Maki S, Konno T, Maeda H: Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor-selective drug targeting with oily contrast medium. Cancer 1985; 56: 751-757.
34. Llovet JM, Di Bisceglie AM, Bruix J, et al: Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
35. Chen RC, Wang CK, Chiang LC, et al: In-traarterial carbon dioxide-enhanced ultrasonogram of hepatocellular carcinoma treated by transcatheter arterial embolization and percutaneous ethanol injection therapy. J Gastroenterol Hepatol 1998; 13: 41-46.
36. Bartolozzi C, Lencioni R, Ricci P, et al: Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US. Radiology 1998; 209: 387-393.
37. Catalano O, Cusati B, Esposito M, et al: The correlation between Doppler echography with a contrast medium and CT in the study of a hepatocarcinoma submitted to chemoembolization. Radiol Med 1998; 95: 608-613.
38. Catalano O, Esposito M, Lobianco R, et al: Hepatocellular carcinoma treated with chemoembolization: assessment with contrastenhanced Doppler ultrasonography. Cardiovasc Intervent Radiol 1999; 22: 486-492.
39. Choi D, Lim HK, Kim SH, et al: Hepatocellular carcinoma treated with percutaneous radiofrequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic responsepreliminary results. Radiology 2000; 217: 558-563.
40. Cioni D, Lencioni R, Bartolozzi C: Therapeutic effect of transcatheter arterial chemoembolization on hepatocellular carcinoma: evaluation with contrast-enhanced harmonic power Doppler ultrasound. Eur Radiol 2000; 10: 1570-1575.
41. Fiore F, Vallone P, Ricchi P, et al: Levovistenhanced Doppler sonography versus spiral computed tomography to evaluate response to percutaneous ethanol injection in hepatocellular carcinoma. J Clin Gastroenterol 2000; 31: 164-168.
42. Meloni MF, Goldberg SN, Livraghi T, et al: Hepatocellular carcinoma treated with radiofrequency ablation: comparison of pulse inversion contrast-enhanced harmonic sonography, contrast-enhanced power Doppler sonography, and helical CT. AJR Am J Roentgenol 2001; 177: 375-380.
43. Cioni D, Lencioni R, Rossi S, et al: Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome. AJR Am J Roentgenol 2001; 177: 783-788.
44. Cedrone A, Pompili M, Sallustio G, et al: Comparison between color power Doppler ultrasound with echo-enhancer and spiral computed tomography in the evaluation of hepatocellular carcinoma vascularization before and after ablation procedures. Am J Gastroenterol 2001; 96: 1854-1859.
45. Choi D, Lim HK, Kim SH, et al: Assessment of therapeutic response in hepatocellular carcinoma treated with percutaneous radiofrequency ablation: comparison of multiphase helical computed tomography and power Doppler ultrasonography with a microbubble contrast agent. J Ultrasound Med 2002; 21: 391-401.
46. Vilana R, Llovet JM, Bianchi L, et al: Barcelona Clinic Liver Cancer Group: Contrastenhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. J Clin Ultrasound 2003; 31: 119-128.
47. Vallone P, Gallipoli A, Izzo F, et al: Local ablation procedures in primary liver tumors: Levovist US versus spiral CT to evaluate therapeutic results. Anticancer Res 2003; 23: 5075-5079.
48. Makuuchi M, Kokudo N, Arii S, et al: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
49. Ding H, Kudo M, Onda H, et al: Contrastenhanced subtraction harmonic sonography for evaluating treatment response in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2001; 176: 661-666.
50. Ding H, Kudo M, Onda H, et al: Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phaseinversion harmonic US: comparison with dynamic CT. Radiology 2001; 221: 721-730.
51. Numata K, Tanaka K, Kiba T, et al: Using contrast-enhanced sonography to assess the effectiveness of transcatheter arterial embolization for hepatocellular carcinoma. AJR Am J Roentgenol 2001; 176: 1199-1205.
52. Morimoto M, Shirato K, Sugimori K, et al: Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181: 65-69.
53. Minami Y, Kudo M, Kawasaki T, et al: Transcatheter arterial chemoembolization of hepatocellular carcinoma: usefulness of coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 180: 703-708.
54. Wen YL, Kudo M, Zheng RQ, et al: Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography. AJR Am J Roentgenol 2003; 181: 57-63.
55. Choi D, Lim HK, Lee WJ, et al: Early assessment of the therapeutic response to radiofrequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultraso-nography with a microbubble contrast agent. J Ultrasound Med 2003; 22: 1163-1172.
56. Shimizu M, Iijima H, Horibe T, et al: Usefulness of contrast-enhanced ultrasonography with a new contrast mode, agent detection imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation therapy. Hepatol Res 2004; 29: 235-242.
57. Pompili M, Riccardi L, Covino M, et al: Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver Int 2005; 25: 954-961.
58. Morimoto M, Nozawa A, Numata K, et al: Evaluation using contrast-enhanced harmonic gray scale sonography after radiofrequency ablation of small hepatocellular carcinoma: sonographic-histopathologic correlation. J Ultrasound Med 2005; 24: 273-283.
59. Vilana R, Bianchi L, Varela M, et al: BCLC Group. Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? Eur Radiol 2006; 16: 2454-2462.
60. Kim HJ, Kim TK, Kim PN, et al: Assessment of the therapeutic response of hepatocellular carcinoma treated with transcatheter arterial chemoembolization: comparison of contrast-enhanced sonography and three-phase computed tomography. J Ultrasound Med 2006; 25: 477-486.
61. Dill-Macky MJ, Asch M, Burns P, et al: Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrastenhanced sonography. AJR Am J Roentgenol 2006; 186(suppl):S287-S295.
62. Kono Y, Lucidarme O, Choi SH, et al: Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 57-65.
63. Lu MD, Yu XL, Li AH, et al: Comparison of contrast-enhanced ultrasound and contrastenhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multicenter study in China. Ultrasound Med Biol 2007; 33: 1736-1749.
64. Xia Y, Kudo M, Minami Y, et al: Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of Sonazoid-enhanced harmonic sonography. Oncology 2008; 75(suppl 1):99-105.
65. Ricci P, Cantisani V, Drudi F, et al: Is contrast-enhanced US alternative to spiral CT in the assessment of treatment outcome of radiofrequency ablation in hepatocellular carcinoma? Ultraschall Med 2009; 30: 252-258.
66. Salvaggio G, Campisi A, Lo Greco V, et al: Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT. Abdom Imaging 2009 (in press).
67. Gallotti A, D'Onofrio M, Ruzzenente A, et al: Contrast-enhanced ultrasonography immediately after percutaneous ablation of hepatocellular carcinoma. Radiol Med 2009; 114: 1094-1105.
68. Luo W, Numata K, Morimoto M, et al: Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma. Eur J Radiol 2009 (in press).
69. Shiozawa K, Watanabe M, Takayama R, et al: Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. J Clin Ultrasound 2010; 38: 182-189.
70. Kisaka Y, Hirooka M, Kumagi T, et al: Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. Liver Int 2006; 26: 1241-1247.
71. Hotta N, Tagaya T, Maeno T, et al: Usefulness of contrast-enhanced ultrasonography with dynamic flow imaging to evaluate therapeutic effects for hepatocellular carcinoma. Hepatogastroenterology 2003; 50: 1867-1871.
72. Nishiharu T, Maeda N, Hara M, et al: Usefulness of enhanced ultrasonography after administration of intravenous contrast agent in the evaluation of therapeutic effect in treatment of hepatocellular carcinoma, and efficacy of percutaneous ethanol injection therapy for residual tumor. Nippon Igaku Hoshasen Gakkai Zasshi 2001; 61: 790-795.
73. Ikeda K, Seki T, Umehara H, et al: Clinicopathologic study of small hepatocellular carcinoma with microscopic satellite nodules to determine the extent of tumor ablation by local therapy. Int J Oncol 2007; 31: 485-491.
74. Livraghi T, Meloni F, Di Stasi M, et al: Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82-89.